NTRB | Nutriband Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	6.45 - 8.11
52 Week Range	3.30 - 11.78
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	612,168
Average Volume	65,813
Shares Outstanding	11,106,200
Market Cap	76,410,656
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-10-01

Valuation
Profitability
Growth
Health
P/E Ratio	-9.69
Forward P/E Ratio	N/A
EPS	-0.71
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	13
Country	USA
Website	NTRB

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

NTRB's peers: APVO, QNRX, LGVN, RNXT, VRAX, INDP, RZLT, TPST, CMRA, FBRX, ANEB, HCWB, ELYM, MOLN, MNOV, CSBR, CYT, ABVC, EDSA, IKT, NRSN, NRXP, QLGN, SLRX

*Chart delayed

Analyzing fundamentals for NTRB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is strong. For more detailed analysis please see NTRB Fundamentals page.

Watching at NTRB technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on NTRB Technicals page.